EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration

Yiqing Jiang iD, Na Wang, Qin Zeng, Jun Liu, Xiaoqin Liu, Guili Cao

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/6434376 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Mutation, online erschienen am 21.05.2026. Verfasst von Yiqing Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First People's Hospital of Zigong, Zigong Medical Science Academy, Zigong, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have become integral to the management of non–small cell lung cancer (NSCLC), yet both primary and acquired resistance remain frequent and are only partially captured by routine biomarkers such as programmed death‐ligand 1 (PD‐L1) immunohistochemistry and tumor mutational burden (TMB). Resistance is increasingly viewed as a multiaxis functional phenotype shaped by antigenicity and neoantigen quality, antigen processing and presentation competence, interferon signaling and adaptive resistance programs, tumor–immune spatial organization, suppressive myeloid/stromal ecosystems, and metabolic constraints that limit effector function. Multiomics profiling provides a practical route to translate genomic event anchors into reproducible, mechanistically interpretable biomarker outputs by assembling coherent evidence chains across genomics, transcriptomics, epigenomics, proteomics, and metabolomics, complemented by spatial assays, digital pathology, and imaging‐derived surrogates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyDrug Resistance, NeoplasmHumansMultiomicsMutationGenomics

Stichwörter der Autor:innen

PD-L1artificial intelligencegenetic variationimmunotherapy resistancemultiomicsnon–small cell lung cancertumor mutational burden

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, First People's Hospital of Zigong, Zigong Medical Science Academy, Zigong, China.

ORCID-Profile: Yiqing Jiang

Zitieren

APA

Jiang, Y., Wang, N., Zeng, Q., Liu, J., Liu, X., & Cao, G. (2026). From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration. Human Mutation, 2026(1). https://doi.org/10.1155/humu/6434376

Vancouver

Jiang Y, Wang N, Zeng Q, Liu J, Liu X, Cao G. From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration. Human Mutation. 2026;2026(1). doi:10.1155/humu/6434376

BibTeX
@article{Jiang2026,
  author = {Jiang, Yiqing and Wang, Na and Zeng, Qin and Liu, Jun and Liu, Xiaoqin and Cao, Guili},
  title = {From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/6434376}
}
Kostenlos starten →